LobbyingElusys Therapeutics Inc Fka Nighthawk Biosciences lobbying by quarter
Elusys Therapeutics Inc Fka Nighthawk Biosciences's latest lobbying report covers Q2 2026, at $280K. The four quarters Q4 2025–Q3 2026 total $700K. Its first report covers Q2 2023; the issues it reports most are Defense and Health Issues.
Elusys Therapeutics Inc Fka Nighthawk Biosciences
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $700K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q2 2023
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q2 2023 | $140K | 1 |
| Q3 2023 | $130K | 1 |
| Q4 2023 | $80K | 1 |
| Q1 2024 | $130K | 1 |
| Q2 2024 | $110K | 1 |
| Q3 2024 | $130K | 1 |
| Q4 2024 | $170K | 1 |
| Q1 2025 | $200K | 1 |
| Q2 2025 | $220K | 1 |
| Q3 2025 | $150K | 1 |
| Q4 2025 | $200K | 1 |
| Q1 2026 | $220K | 1 |
| Q2 2026 | $280K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Defense$1.1M · 13 reports
- Health issues$1.1M · 13 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- Defense, Dept of (DOD)13 reports
- Health & Human Services, Dept of (HHS)13 reports
- HOUSE OF REPRESENTATIVES13 reports
- Office of Science & Technology Policy (OSTP)13 reports
- SENATE13 reports
- Natl Security Council (NSC)10 reports
- Homeland Security, Dept of (DHS)5 reports
- Office of the Vice President of the United States2 reports
- State, Dept of (DOS)2 reports
Firms it paid
| Firm | ||
|---|---|---|
| In-houseElusys Therapeutics Inc Fka Nighthawk Biosciences | $2.2M | 13 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/18for Q2 | In-house | $280K |
| 04/20for Q1 | In-house | $220K |
| 01/20for Q4 2025 | In-house | $200K |
| 25/10/20for Q3 2025 | In-house | $150K |
| 25/07/21for Q2 2025 | In-house | $220K |
| 25/04/21for Q1 2025 | In-house | $200K |
| 25/01/20for Q4 2024 | In-house | $170K |
| 24/10/21for Q3 2024 | In-house | $130K |
| 24/07/19for Q2 2024 | In-house | $110K |
| 24/04/22for Q1 2024 | In-house | $130K |
| 24/01/20for Q4 2023 | In-house | $80K |
| 23/10/20for Q3 2023 | In-house | $130K |
| 23/08/03for Q2 2023 | In-house | $140K |
| 23/07/20for Q2 2023 | In-house | Under $5,000 |
| 23/06/01for Q2 2023 | In-house | Under $5,000 |